AzTrials
AzTrials

Type 2 Diabetes MellitusPhase 2NCT04217291

The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus

A Phase 2 study testing SY-004 in people with Type 2 Diabetes Mellitus, run by Suzhou Yabao Pharmaceutical R&D Co., Ltd. at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study in patients with type 2 diabetes mellitus (T2DM). Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Type 2 Diabetes Mellitus
What is being tested?
SY-004
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
200 participants
Where
1 siteChina
Study dates
10 Dec 2019to 9 Jul 2021
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Gender is not limited.
  • Age at screening: ≥ 18 years old, ≥ 75 years old.
  • According to WHO diagnostic criteria and classification in 1999, type 2 diabetes was diagnosed, with a course of at least 3 months.
  • During screening and before randomization, 18kg / m2 ≤ BMI ≤ 35kg / m2.
  • At the time of screening, they had been treated with diet or exercise for at least 3 months.
  • No antidiabetic drugs were used at the time of screening, or the antidiabetic drugs were used irregularly within 3 months before screening (the cumulative use of antidiabetic drugs in the past 3 months was no more than 2 weeks and no antidiabetic drugs were used in the past 1 month).
Show all 12Show fewer
  • During screening, 7% of the samples detected by local laboratory were ≤ HbA1c ≤ 11%.
  • Before randomization, the central laboratory tested 7% ≤ HbA1c ≤ 11%.
  • Fasting blood glucose (FBG) of 7-13.3 mmol / L (including boundary value) was measured in the central laboratory before randomization.
  • The subjects must have informed consent before the study, and signed the written informed consent voluntarily.
  • The subjects were willing and able to use the home blood glucose meter for self blood glucose monitoring.
  • The subjects were able to communicate well with the researchers and complete the study according to the protocol.

Who cannot join

  • Staff members and their immediate family members of the research project. Lineal relatives refer to persons with consanguineous or legal relationships, including spouses, parents, children, brothers and sisters.
  • Any of the following drugs or treatments were used prior to screening:
  • In the past six months, insulin therapy has been used for more than one month, or insulin therapy is needed at present.
  • Long acting GLP-1 has been used in the past 6 months.
  • Glucokinase activator (GKA) was used in the past 6 months.
  • In the past 6 months, I have received weight-loss drugs or any weight-loss treatment (such as surgery, excessive diet and exercise therapy) that leads to weight instability.
Show all 40Show fewer
  • Participated in clinical trials of any drug or medical device in the past 3 months.
  • Other drugs that may affect blood glucose metabolism have been used in the past 8 weeks, including growth hormone treatment, and long-term or repeated intermittent systemic glucocorticoids (intravenous, oral or intra-articular administration for more than 2 weeks or repeated courses, except inhalation or local external use), etc.
  • Strong CYP3A inducers or strong CYP3A inhibitors have been used in the past two weeks or are planned to be used in the near future (refer to appendix 12.5.1).
  • Drugs that are likely to cause torsade de pointes have been used in the past two weeks or planned in the near future (refer to appendix 12.5.2).
  • Prior to screening, there was a history or evidence of any of the following diseases:
  • Type 1 diabetes, special type diabetes and secondary diabetes.
  • Significant clinical cardiovascular events have occurred in the past 6 months (refer to appendix 12.3).
  • Patients with clinically significant peripheral vascular lesions, such as ischemic ulcer or gangrene, diabetic foot ulcer and infection.
  • There is sufficient evidence for the presence of active diabetic proliferative retinopathy or maculopathy that is unstable or in need of treatment.
  • there are obvious autonomic neuropathy, such as urinary retention, orthostatic hypotension, diabetic diarrhea or gastroparesis.
  • Have a history of acute or chronic pancreatitis.
  • Ketoacidosis, diabetic acidosis or hyperosmolar nonketotic coma have occurred in the past 6 months and need to be hospitalized.
  • In the past 6 months, serious hypoglycemic events with unknown causes (need other people's help to recover); or frequent hypoglycemia: for example, more than two hypoglycemic events (blood glucose ≤ 3.9mmol / L) occurred in the first month before screening.
  • Any endocrine system disease related to blood glucose (such as hyperthyroidism, acromegaly, Cushing's syndrome), immune system disease or other diseases that are unstable or need treatment are not suitable for the study according to the judgment of researchers.
  • Have other diseases that affect glucose metabolism or are taking drugs that significantly affect glucose metabolism.
  • Severe trauma or acute infection that may affect blood glucose control has occurred in the past month.
  • Suffer from serious cardiovascular disease, respiratory system disease, gastrointestinal disease, liver dysfunction, renal dysfunction, endocrine disease (except diabetes), blood system disease, nervous system disease, and the disease status can significantly change the absorption, distribution, metabolism and excretion of the test drug, or taking the test drug will increase the risk of the subject or affect the analysis of the research results.
  • There are any types of malignant tumors (whether cured or not).
  • A history of diseases that may cause hemolysis or red blood cell instability that affect HbA1c detection, such as hemoglobinopathy (such as sickle cell anemia or thalassemia, ferriblastic anemia).
  • History of alcohol and drug abuse. Drink more than 21 units (male) or 14 units (female) of alcohol per week (1 unit is about 360 ml of beer or 45 ml of spirits or 150 ml of wine with 40% alcohol).
  • There are mental or nervous system diseases, unwillingness to communicate or language barriers, and insufficient understanding and cooperation.
  • There is any laboratory inspection index meeting the following standards at screening or random:
  • In the absence of pacemaker, 12 lead ECG showed second or third degree atrioventricular block, or corrected qtcb > 450ms (male) or > 470ms (female).
  • eGFR<60ml/(min•1.73m2)。
  • ALT > 1.5 times the upper limit of normal value (× ULN), AST > 1.5 × ULN, TBIL > 1.5 × ULN.
  • Hypertension (systolic blood pressure ≥ 160mmhg or diastolic blood pressure ≥ 100mmhg) that cannot be controlled by drugs or other treatment means exists.
  • Hypertriglyceridemia (triglyceride > 500mg / dl (5.70mmol / L)) was found which could not be controlled by drugs or other treatments.
  • Hemoglobin < 90g / L.
  • The serological evidence of infectious virus is positive, including hepatitis B, hepatitis C, HIV and Treponema pallidum.
  • Fasting C-peptide < 1.0 ng / ml (333 pmol / L).
  • Fertile eligible subjects (men and women) disagreed with the use of reliable contraceptive methods during the study and at least one month after the last administration.
  • Pregnant or lactating women.
  • Allergic to the active ingredient agratine hydrochloride, or severe allergic constitution / severe allergic history.
  • Other circumstances judged by the sponsor or researcher as unsuitable for the study.

Trial locations and contacts

1 site in 1 country.

China1 site

  • PLA General Hospital

    Beijing, Beijing Municipality, 100853

Other trials in China

About this study

Official title: Evaluation of the Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study in patients with type 2 diabetes mellitus (T2DM).

Read the detailed description

200 cases will be included and divided into four groups with 50 cases in each group

Being tested
SY-004, SY-004 matching placebo
Medical subject headings
Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SY-004Drug

    Take orally once a day

  • SY-004 matching placeboOther

    Take orally once a day

Study groups in NCT04217291
Study groupRoleWhat they receive
SY-004-1Experimentala dose of 80mg/day taken orally for two weeks, and a dose of 80mg/day for 14 weeks from the third week
Receives: Drug: SY-004
SY-004-2Experimentala dose of 80mg/day taken orally for two weeks, and a dose of 160mg/day for 14 weeks from the third week.
Receives: Drug: SY-004
SY-004-3Experimentala dose of 80mg/day orally in the first week, a dose of 160mg/day in the second week and a dose of 240mg/day for 14 weeks from the third week.
Receives: Drug: SY-004
placeboPlacebo comparatora dose of SY-004 matching placebo taken orally
Receives: Other: SY-004 matching placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in Glycosylated Hemoglobin A1c (HbA1c)

    Changes in Glycosylated Hemoglobin A1c relative to baseline at 16 weeks compared to placebo.

    Measured: 16 weeks

Secondary outcomes (8)

  1. the proportion of subjects whose Glycosylated Hemoglobin A1c (HbA1c) was less than 7%.

    At the end of 16 weeks, the proportion of subjects whose Glycosylated Hemoglobin A1c was less than 7% .

    Measured: 16 weeks

  2. The proportion of subjects with Glycosylated Hemoglobin A1c (HbA1c) < 6.5%

    The proportion of subjects with Glycosylated Hemoglobin A1c < 6.5% at 16 weeks after administration of SY-004.

    Measured: 16 weeks

  3. Changes in Glycosylated Hemoglobin A1c (HbA1c)

    The change of Glycosylated Hemoglobin A1c relative to the baseline after 8 weeks of treatment with SY-004.

    Measured: 8 weeks

  4. the proportion of subjects whose Glycosylated Hemoglobin A1c (HbA1c) was less than 7%

    At the end of 8 weeks, the proportion of subjects whose Glycosylated Hemoglobin A1c was less than 7% .

    Measured: 8 weeks

  5. The proportion of subjects with Glycosylated Hemoglobin A1c (HbA1c) < 6.5%

    The proportion of subjects with Glycosylated Hemoglobin A1c < 6.5% at the end of 8 weeks.

    Measured: 8 weeks

  6. Changes in fasting blood glucose (FPG) relative to the baseline

    Changes in fasting blood glucose (FPG) relative to the baseline at 1, 2, 4, 8, 12 and 16 weeks after administration of SY-004.

    Measured: 1、2、4、8、12、16weeks

  7. Changes in postprandial blood glucose auc0-2h

    Changes in postprandial blood glucose auc0-2h ( 0-2h blood glucose AUC of Mixed-Meal-Tolerance-Test ) relative to baseline at 16 weeks after administration of SY-004.

    Measured: 16 weeks

  8. Changes in abdominal weight relative to baseline at 8 and 16 weeks.

    Changes in abdominal weight relative to baseline at 8 and 16 weeks after administration of SY-004.

    Measured: 8、16weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Jan 2020
  2. Study start10 Dec 2019
  3. Primary completion9 Jul 2021
  4. Study completion9 Jul 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
200 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04217291
Sponsor's protocol ID
SY004003
Status last verified
May 2021
First submitted
30 Dec 2019
Last updated
18 May 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing SY-004 in people with Type 2 Diabetes Mellitus, run by Suzhou Yabao Pharmaceutical R&D Co., Ltd. at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 40 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 May 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in Glycosylated Hemoglobin A1c (HbA1c) (time frame: 16 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04217291.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2022.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in